Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW BRUNSWICK, N.J., Aug. 19, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that Mr.

Alex Gorsky to Serve as Executive Chairman and Transition Role of Chief Executive Officer of Johnson & Johnson to Joaquin Duato, Effective January 3, 2022

Johnson & Johnson (NYSE: JNJ) COVID-19 vaccines bottled and packaged at Aspen's site meant for Africa are exported to the European Union, the New York Times reported earlier this week.  Even though South Africa ordered 31 million doses of J&J's shot back in April, the country is still waiting to receive the bulk of its order, the Times reported on Monday.

Europe Faces Backlash For Importing JNJ COVID-19 Shots From South Africa: Reuters

Janssen, a unit of Johnson & Johnson (NYSE: JNJ), announced preliminary data from the Phase 1 CHRYSALIS study evaluating Rybrevant (amivantamab-vmjw) for non-small cell lung cancer (NSCLC) with mesenchymal-epithelial transition (MET) exon 14 skipping (METex14) mutations. A total of 19 patients with METex14 mutations received either a high or low dose of Rybrevant, and 14 of them were evaluable.

Johnson & Johnson Touts Rybrevant Label Expansion After Rare Lung Cancer Approval

BioNTech SE

Moderna

Pfizer

In order to provide better protection to the American people from rising COVID-19 cases due to the surge of the Delta variant, U.S. health officials are recommending use of a booster dose for individuals starting this fall.

US Set to Receive COVID-19 Vaccine Booster Dose Next Month

The stock price of ​Johnson & Johnson (NYSE: JNJ) has seen a rise of over 7% over the last twenty-one trading days, and it is also up 15% year-to-date. Note that such a move for JNJ stock is uncommon, and it has occurred less than 90 times over the last 10 years.

Will The Gains Continue For Johnson & Johnson Stock After A 7% Rise In A Month?

A new South African study shows the one-dose vaccine is highly effective against the delta variant.

Here's Why Johnson & Johnson's Vaccine Could Overtake Both Pfizer and Moderna

American Express

Cisco Systems

Goldman Sachs

Harvard Bioscience

Home Depot

Honeywell

JPMorgan Chase & Co

Microsoft

Procter & Gamble

Silvergate Capital Corp

Visa

Two new Breakout Stocks for Week 32 with better than 10% short-term upside potential. The ETF/ETN forecast section now goes out in a separate article. Following the Momentum Gauges®, the portfolio is up +49.8% YTD with a record 18 out of 32 weeks this year in negative market conditions above the 40 MG level.

Week 33 MDA Breakout Stocks - August 2021: Short-Term Picks To Give You An Edge

Archer-Daniels-Midland Company

Aflac

Chevron

Hershey

Main Street Capital

NextEra Energy

NIKE

Raytheon Technologies

Target

Union Pacific

Walgreens

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: August 17-30, 2021

These strengthening tailwinds will power future returns.

4 Reasons to (Still) Be Optimistic About Coronavirus Vaccine Stocks

Activision Blizzard

Ampco-Pittsburgh

Lululemon Athletica

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Activision Blizzard among others.

Activision Blizzard Among Today's Trending Stocks

Adobe

Danaher

Alphabet

COVID-19 cases have spiked recently due to a highly transmissible strain. Here's a list of delta variant stocks that could get a boost as cases continue to ramp up.

6 Stocks to Buy as Delta Variant Cases Surge

NEW BRUNSWICK, N.J., Aug. 12, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will participate in the Morgan Stanley 19th Annual Global Healthcare Conference on Wednesday, September 15 th.

Johnson & Johnson to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

The World Health Organization plans to test three new drugs as possible treatments for people who have been hospitalized for COVID-19. This includes Ipca Laboratories Ltd.

WHO to study whether three drugs, including J&J's Remicade, can help hospitalized COVID-19 patients

Amazon

Lockheed Martin

Zoetis

McDonald's

These seven stocks to buy right now for a bear market are also generally strong in bull markets. Their resistance is the key element.

7 Best Bear Market Stocks to Buy Now in Preparation for a Downturn

Atea Pharmaceuticals

Merck

Sorrento Therapeutics Inc

Vaxart

You may have thought the moment of relevancy for these biotech stocks was over, but the Delta variant has changed their prospects. The post 7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught appeared first on InvestorPlace.

7 Biotech Stocks to Buy Amid the Delta Variant's Onslaught

Abbott Labs

Vertex Pharmaceuticals

These three giants of the healthcare sector aren't too big to buy with just a couple hundred bucks.

3 of the Best Stocks You Can Buy With $200 or Less

AGNC Investment

Philip Morris

One of the best ways to fight back against inflation is to put your cash to work in time-tested companies.

4 Value Stocks That'll Help You Trounce Inflation

Provident Financial Services

The journey to financial freedom does not take breaks and one must continue to persevere through uncertainty, put cash to work and push that forward dividend income forward. Investing consistently in Dividend Income Stocks allows you to create & build another income source.

Dividend Stock Purchase: Lanny's July 2021 Summary

News for Johnson & Johnson Stock (JNJ)